This mechanism underlies the efficacy of gemtuzumab ozogamicin, an anti-CD33 ADC approved for acute myeloid leukemia (AML), which delivers N-acetyl-γ-calicheamicin dimethyl hydrazide with an IC50 of 10–50 pM in leukemia cell lines [114]. This evidence concerns the gene CD33 and acute myeloid leukemia.